FDA Approves Updated COVID-19 Vaccines Targeting XFG Variant
The FDA has approved updated COVID-19 vaccines for the 2026-2027 season from three major manufacturers: Pfizer-BioNTech, Moderna, and Sanofi-Novavax. These updated vaccines target the XFG variant of the coronavirus. Approval is focused on people 65 and older and younger individuals with underlying health conditions that increase their risk of severe illness. The vaccines are based on mRNA technology, except for Sanofi's protein-based alternative. Manufacturers say vaccines will be available at pharmacies and clinics in coming weeks. The approval comes as COVID-19 cases are rising, with test positivity rates climbing across all states. Federal health officials state the updated vaccines meet rigorous standards for safety and effectiveness. However, questions remain about formal government recommendations and how the change from universal to risk-based guidance will affect access in different states.
Key facts
- FDA approved updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Sanofi-Novavax on August 27, 2026
- All three vaccines target the XFG variant, a subvariant of the JN.1 coronavirus strain
- Vaccines are approved for people 65 and older and younger people ages 5-12 with underlying health conditions
- Pfizer shot approved for ages 5 and older with risk factors; Moderna approved for ages 6 months and older; Sanofi approved for ages 12 and older
- Current COVID-19 test positivity rate approaching 5 percent as of mid-August 2026, rising in all states
- Previous vaccine formulas provided approximately 58 percent protection against hospitalization
How different outlets framed it
Left-leaning coverage: Left-leaning outlets emphasize that vaccines provide critical protection against severe illness, hospitalization, and death, especially for vulnerable populations. They highlight that the updated formula targets the most current variant and that vulnerable people should have equitable access to this protection as part of comprehensive public health strategy.
Right-leaning coverage: Right-leaning sources question whether new vaccines are necessary given low current hospitalization and death rates, and some raise concerns about the approval process and the decision to conduct single-arm rather than placebo-controlled trials. They note that Health Secretary Robert F. Kennedy Jr. has been critical of mRNA vaccines against respiratory diseases.
Limits of this briefing
Federal vaccine recommendations have shifted from universal guidance to individual decision-making with healthcare provider consultation, creating potential disparities in vaccine access across states. Some sources also note that formal CDC guidance on these specific vaccines has not yet been issued.
Sources
- CNN: FDA approves updated Covid-19 vaccines Centre
- The Washington Post: FDA just approved updated covid shots. Here's what to know as cases edge upward. Centre
- The Hill: FDA approves updated COVID-19 vaccines Centre
- ZeroHedge: FDA Approves 3 New COVID-19 Vaccines Right
- The Epoch Times: FDA Approves 4 New COVID-19 Vaccines Right